These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 11469485

  • 1. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment.
    Wolfe F, Rehman Q, Lane NE, Kremer J.
    J Rheumatol; 2001 Jul; 28(7):1704-11. PubMed ID: 11469485
    [Abstract] [Full Text] [Related]

  • 2. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 3. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y, Shi N, John A.
    Bull NYU Hosp Jt Dis; 2008 Jan; 66(2):77-85. PubMed ID: 18537774
    [Abstract] [Full Text] [Related]

  • 4. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centres.
    J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
    [Abstract] [Full Text] [Related]

  • 5. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 6. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 7. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA, Bingham CO.
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X, Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group, Club Rhumatismes et Inflammation, French Society of Rheumatology.
    Arthritis Rheum; 2009 Apr 15; 61(4):425-34. PubMed ID: 19333993
    [Abstract] [Full Text] [Related]

  • 15. Assessment and management of rheumatoid arthritis.
    Haraoui B.
    J Rheumatol Suppl; 2009 Jun 15; 82():2-10. PubMed ID: 19509324
    [Abstract] [Full Text] [Related]

  • 16. From aspirin to biologics: therapeutic implications for rheumatoid arthritis.
    Wright V.
    J Rheumatol Suppl; 1992 Jan 15; 32():95-7. PubMed ID: 1613740
    [Abstract] [Full Text] [Related]

  • 17. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C, Ehlin AG, Klareskog L, Lindblad S, Montgomery SM.
    Ann Rheum Dis; 2006 Aug 15; 65(8):1102-5. PubMed ID: 16322085
    [Abstract] [Full Text] [Related]

  • 18. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C.
    Dtsch Med Wochenschr; 2011 Feb 15; 136(5):203-5. PubMed ID: 21271482
    [Abstract] [Full Text] [Related]

  • 19. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug 15; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 20. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician.
    Martin RW, Head AJ, René J, Swartz TJ, Fiechtner JJ, McIntosh BA, Holmes-Rovner M.
    J Rheumatol; 2008 Apr 15; 35(4):618-24. PubMed ID: 18278840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.